ZeaVision gets strategic investment from DSM Venturing

ZeaVision gets strategic investment from DSM Venturing

Maker of the EyePromise brand of doctor-recommended nutraceuticals has received an equity investment from the corporate venture arm of Royal DSM.

ZeaVision Holdings Inc., maker of the EyePromise® brand of doctor-recommended nutraceuticals, has received an equity investment from DSM Venturing, the corporate venture arm of Royal DSM, the global life sciences and material sciences company.

ZeaVision President Chris Barber commented: "DSM has a long history of excellence and innovation in the nutrition industry. We are pleased to welcome DSM as a strategic investor which offers unique potential to strengthen ZeaVision's leadership position in the ocular nutrition market."

Greg McParland, senior investment manager of DSM Venturing, said: "This investment is at the core of our strategy to support emerging companies in our ecosystem and create new business opportunities. We commend ZeaVision for its innovative and science based approach to eye care and look forward to supporting the team in the expansion of their business."

Will Black, vice president of marketing for DSM Nutritional Products, said: "DSM is excited to invest in the company. ZeaVision has made a significant contribution to expand research and scientific understanding of the role of nutrition in eye health."

 

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish